These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 27919413)

  • 1. New choices for treatment with subcutaneous immunoglobulins.
    Pleguezuelo DE; Sánchez-Ramón S
    Med Clin (Barc); 2017 Jan; 148(2):86-90. PubMed ID: 27919413
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunoglobulin therapy: methods of delivery.
    Ballow M
    J Allergy Clin Immunol; 2008 Nov; 122(5):1038-9. PubMed ID: 18804269
    [No Abstract]   [Full Text] [Related]  

  • 3. IgG replacement therapy, no size fits all.
    Bonilla FA
    Clin Immunol; 2011 May; 139(2):107-9. PubMed ID: 21420364
    [No Abstract]   [Full Text] [Related]  

  • 4. [Immunoglobulins and immune deficiency: methods of administration].
    Suarez F
    Rev Med Interne; 2005 Oct; 26 Spec No 1():25-8. PubMed ID: 16475260
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunoglobulin Replacement Therapy for Primary Immunodeficiency.
    Sriaroon P; Ballow M
    Immunol Allergy Clin North Am; 2015 Nov; 35(4):713-30. PubMed ID: 26454315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies.
    Canessa C; Iacopelli J; Pecoraro A; Spadaro G; Matucci A; Milito C; Vultaggio A; Agostini C; Cinetto F; Danieli MG; Gambini S; Marasco C; Trizzino A; Vacca A; De Mattia D; Martire B; Plebani A; Di Gioacchino M; Gatta A; Finocchi A; Licciardi F; Martino S; De Carli M; Moschese V; Azzari C
    Int J Immunopathol Pharmacol; 2017 Mar; 30(1):73-82. PubMed ID: 27927705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of systemic lupus erythematosus with subcutaneous immunoglobulin.
    Brasileiro A; Fonseca Oliveira J; Pinheiro S; Paiva-Lopes MJ
    Lupus; 2016 May; 25(6):663-5. PubMed ID: 26846694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies.
    Berger M; Rojavin M; Kiessling P; Zenker O
    Clin Immunol; 2011 May; 139(2):133-41. PubMed ID: 21353644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacoeconomics of immunoglobulins in primary immunodeficiency.
    Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):375-86. PubMed ID: 19670998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Subcutaneous immunoglobulin substitution and therapy].
    Gulácsy V; Maródi L
    Orv Hetil; 2011 Jan; 152(2):64-7. PubMed ID: 21177233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recommended indications for the administration of polyclonal immunoglobulin preparations.
    Delforge M; Farber CM; Spath P; Kaveri S; Witte T; Misbah SA; Hübner R; Haerynck F; Latinne D; Muylle L; Toungouz M; Deneys V;
    Acta Clin Belg; 2011; 66(5):346-60. PubMed ID: 22145269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Hospital-Based Intravenous Immunoglobulin and Home-Based Self-Administered Subcutaneous Immunoglobulin in Polish Children with Primary Immunodeficiency Diseases.
    Bal K; Kałuzińska-Parzyszek I; Sobocińska A; Podlecka D; Jerzyńska J; Stelmach I
    Indian J Pediatr; 2015 Aug; 82(8):768-9. PubMed ID: 25786586
    [No Abstract]   [Full Text] [Related]  

  • 13. Another subcutaneous immune globulin (Cuvitru) for primary immunodeficiency.
    Med Lett Drugs Ther; 2017 May; 59(1521):e88-e89. PubMed ID: 28520701
    [No Abstract]   [Full Text] [Related]  

  • 14. [Patient handout. Common variable immunodeficiency].
    Revue du Praticien
    Rev Prat; 2007 Oct; 57(15):1702. PubMed ID: 18080430
    [No Abstract]   [Full Text] [Related]  

  • 15. [The new domestic immunoglobulin G gabriglobin in complex therapy of immunodeficiency states and infectious pathology].
    Pas'ko VG; Latysheva TV; Nikiforov VV; Mostovskaia EV; Denisov AK; Kondrashin IuI
    Voen Med Zh; 2006 Jul; 327(7):40-2. PubMed ID: 16977880
    [No Abstract]   [Full Text] [Related]  

  • 16. [Immunoglobulin therapy of primary humoral immunologic deficiencies].
    Bordigoni P
    Rev Prat; 2007 Oct; 57(15):1691-8. PubMed ID: 18080428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Replacement therapy with subcutaneous immunoglobulin in primary immunodeficiency in children].
    Pac M
    Pol Merkur Lekarski; 2011 Jun; 30(180):413-6. PubMed ID: 21751550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential Anti-Tumor Activity of Intravenous and Subcutaneous Immunoglobulin.
    Danieli MG; Gelardi C; Pedini V; Gabrielli A
    Isr Med Assoc J; 2018 Dec; 20(12):782-783. PubMed ID: 30550011
    [No Abstract]   [Full Text] [Related]  

  • 19. Considerations for the optimal use of immunoglobulin.
    Navarro RP; Ballow M; Fenrick B; Pezalla EJ
    Am J Manag Care; 2012 Jun; 18(4 Suppl):S67-78. PubMed ID: 22774920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies.
    Dams ET; van der Meer JW
    Lancet; 1995 Apr; 345(8953):864. PubMed ID: 7898254
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.